COMP <GO>
CUVL vs RTX // OPERATING MARGIN
Clinuvel Pharmaceuticals Limited (NASDAQ) VS. RTX Corporation (NYSE) • 15-METRIC TALLY: CUVL 5
— RTX 5
▲ OPERATING MARGIN LEADER: CUVL
LAST: $5.15 (+1.58%) • MKT CAP: $257.8M
operating-margins
43.40%
LAST: $199.40 (+1.82%) • MKT CAP: $269.08B
operating-margins
10.50%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CUVL VS. RTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CUVL | RTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 81.20% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 7.20% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 9.7x | 26.5x | -16.80 | CUVL | /valuation <GO> |
| Free Cash Flow Yield | 10.51% | 2.95% | +7.56 | CUVL | /fcf-yield <GO> |
| Operating Margin ACTIVE | 43.40% | 10.50% | +32.90 | CUVL | /operating-margins <GO> |
| Net Profit Margin | 37.80% | 7.60% | +30.20 | CUVL | /net-margins <GO> |
| Revenue Growth (YoY) | 5.50% | 9.70% | -4.20 | RTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.66% | 1.33% | -0.67 | RTX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.73 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 9/9 | -3.00 | RTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.7 | 60.0 | -22.33 | RTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.3x | 37.2x | -26.90 | CUVL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $257.8M | $269.08B | -$268.82B | RTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CUVL REV | RTX REV | CUVL GROSS % | RTX GROSS % | CUVL FCF | RTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $61.1M | $88.60B | 81.2% | — | $27.1M | $7.94B |
| FY 2024 | $57.9M | $80.74B | 81.5% | — | $20.1M | $4.53B |
| FY 2023 | — | $68.92B | — | — | — | $4.78B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CUVL // BETA —
RTX // BETA 0.92